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Infection Does Not Involve Toll-Like Receptor 2
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Christopher C. Norburya
Department of Microbiology and Immunology, College of Medicine, Pennsylvania State University, Hershey, Pennsylvania, USAa; Department of Microbiology and
Immunology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USAb; Immune Cell Development and Host Defense Program, Research
Institute of Fox Chase Cancer Center, Philadelphia, Pennsylvania, USAc
ABSTRACT
Although the pattern recognition receptor Toll-like receptor 2 (TLR2) is typically thought to recognize bacterial components, it
has been described to alter the induction of both innate and adaptive immunity to a number of viruses, including vaccinia virus
(VACV). However, many pathogens that reportedly encode TLR2 agonists may actually be artifactually contaminated during
preparation, possibly with cellular debris or merely with molecules that sensitize cells to be activated by authentic TLR2 ago-
nists. In both humans andmice, the most relevant natural route of infection with VACV is through intradermal infection of the
skin. Therefore, we examined the requirement for TLR2 and its signaling adaptor MyD88 in protective immunity to VACV after
intradermal infection. We find that although TLR2 may recognize virus preparations in vitro and have a minor role in prevent-
ing dissemination of VACV following systemic infection with large doses of virus, it is wholly disposable in both control of virus
replication and induction of adaptive immunity following intradermal infection. In contrast, MyD88 is required for efficient
induction of CD4 T cell and B cell responses and for local control of virus replication following intradermal infection. However,
evenMyD88 is not required to induce local inflammation, inflammatory cytokine production, or recruitment of cells that re-
strict virus from spreading systemically after peripheral infection. Thus, an effective antiviral response does require MyD88, but
TLR2 is not required for control of a peripheral VACV infection. These findings emphasize the importance of studying relevant
routes of infection when examining innate sensing mechanisms.
IMPORTANCE
Vaccinia virus (VACV) provides the backbone for some of the most widely used and successful viral vaccine vectors and is also
related to the human pathogens Cantagalo virus andmolluscum contagiosum virus that infect the skin of patients. Therefore, it
is vital to understand the mechanisms that induce a strong innate immune response to the virus following dermal infection.
Here, we compare the ability of the innate sensing molecule Toll-like receptor 2 (TLR2) and the signaling molecule MyD88 to
influence the innate and adaptive immune response to VACV following systemic or dermal infection.
Pattern recognition receptors (PRRs) are crucial for innate im-munity, through recognition of common molecular patterns
distinctive of pathogens. Activation through PRR leads to the in-
duction of type I interferons and inflammatory cytokines. Toll-
like receptors (TLRs) make up a family of PRRs that have an N-
terminal extracellular domain made up of leucine-rich repeats
(LRRs), a single transmembrane domain, and a cytoplasmic TIR
domain shared by both the TLR and interleukin-1 receptor (IL-
1R) families. The LRR domain is the main source of variability
among TLRs and of genetic diversity within a single TLR (1).
Toll-like receptor 2 (TLR2) is a cell surface TLR that uniquely
heterodimerizes with either TLR1 or TLR6 and directly binds
adaptor protein MyD88, signaling to upregulate cytokines and
chemokines that foster inflammation (2). The first TLR2 agonists
identified were bacterial lipoproteins (3). In practice, TLR2 has
been reported to recognize a wider range of pathogens than any
other TLR, including fungi (4), protozoans (5), worms (6),Myco-
plasma (7), Gram-positive and -negative bacteria (8, 9), DNA vi-
ruses (10), and RNA viruses (11), as well as host molecules such as
HMGB1 (12). However, concern is growing that many reported
TLR2 agonists are artifacts of possible contamination, cellular de-
bris, or merely molecules that sensitize cells to be activated by
authentic TLR2 agonists (13, 14).
TLR2 also offers diversity in its downstream signaling effects
(15). In addition to inducing proinflammatory cytokines in its
classical role as a MyD88-dependent cell surface receptor, it also
activates type I interferon expression with both viral and bacterial
ligands (16, 17), a pathway that requires internalization and may
even involve the Trif adaptor molecule, rather than MyD88 (18).
One virus that has been suggested to encode a TLR2 agonist(s) is
vaccinia virus (VACV), a double-stranded DNA (dsDNA) or-
thopoxvirus that infects a variety of animals, including mice, hu-
mans, and cattle. VACV has long been a promising vector for
immunization and gene therapy and is important for human
health as the vaccine given to protect people from smallpox, an
often-fatal disease caused by the closely related variola virus (19,
20). Although many animal studies examine immunity to VACV
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induced through systemic intraperitoneal (i.p.) or intravenous
(i.v.) routes, the route of infection thatmost closely resembles that
used during human immunization, infection of humans with the
related poxvirus molluscum contagiosum virus (21), and the
route that mimics natural infection of mice with the highly ho-
mologous orthopoxvirus ectromelia virus (ECTV), is the intra-
dermal (i.d.) route (22). Indeed, pathogenesis experiments reveal
a role for highly conserved immunomodulatorymolecules follow-
ing intradermal, but not other, routes of infection, indicating that
this is a natural route of infection (23). In vitro myeloid cells can
use TLR2 to detect an unknown component within preparations
ofVACV (17) and the highly attenuated vaccinia virus strainMVA
(24), but the specific VACV TLR2 ligand (if any) present within
these preparations remains uncharacterized.
In vivo evidence for TLR2 as a VACV sensor is very inconsis-
tent. One study found that TLR2 andMyD88 knockout mice suf-
fered increased viral titers despite continued high levels of serum
beta interferon (IFN-) (25), while another found no impact on
viral titers but a significant decrease in serum IFN- (26). VACV
may also directly activate CD8 T cells through TLR2 (27), sug-
gesting that it is important for developing effectivememory aswell
as an innate response. However, it is also reported that, although
VACV stimulates CD8 T cell activation and differentiation in a
MyD88-dependentmanner, theMyD88 knockout phenotype was
not shared by TLR2, TLR4, TLR9, or IL-1R knockouts (28). Fur-
thermore, all in vivo experiments on deficiencies in TLR2/MyD88
signaling thus far have used intraperitoneal or intravenous infec-
tion with large doses of VACV, which work well to induce sys-
temic inflammation, viremia, and infection of multiple organ sys-
tems but are quite distinct from the intradermal and intranasal
routes of infection that most poxviruses have evolved to utilize.
Infection via the intraperitoneal or intravenous routes may allow
access to innate immune cells that are not normally exposed to
virus. Indeed, evidence from other pathogens (29–31) suggests
that although TLR2-deficient animals are highly susceptible to
systemic infection, they may respond similarly to wild-type (WT)
animals when infected intradermally, even thoughmany cell types
in the skin express TLR2 (32).
In the present study, we investigatedTLR2-MyD88 signaling in
themurine immune system following intradermal poxvirus infec-
tion. We observed that MyD88/ mice had enhanced viral rep-
lication and more rapid tissue destruction and were impaired in
their development of CD4 T cell and antibody responses. How-
ever, TLR2/mice were capable of adequately controlling virus
spread, clearing virus from the skin, and establishing CD4 T cell
and antibody responses to VACV infection. Though TLR2/
cells were impaired in responding to VACV with proinflamma-
tory cytokines in vitro, and it is reported that TLR2/mice have
a similar impairment early in intravenous infection (33), we found
no difference between TLR2/ and TLR2/ mice in recruit-
ment of myeloid cells to the ear or in production of cytokines or
interferon-stimulated genes following infection. These results
suggest that any role for TLR2 in host response to vaccinia virus is
superfluous when the virus enters the body through a natural
route.
MATERIALS AND METHODS
Animals.C57BL/6mice were purchased fromCharles River Laboratories.
TLR2/ (catalog no. 004650),MyD88/ (catalog no. 009088), IL-6/
(catalog no. 002650), LysM:cre (catalog no. 004781), and MyD88:flox
(catalog no. 008888) mice were purchased from Jackson Laboratory and
subsequently bred at the Hershey Medical Center. LysM:wt/cre MyD88:
flox/flox mice were generated by first breeding LysM:cre andMyD88:flox
mice to create LysM:cre MyD88:flox double transgenics and then breed-
ing LysM:cre MyD88:flox mice to MyD88:flox mice. All knockout mouse
strains were on the C57BL/6 background after a minimum of 12 back-
crosses to this strain. All animals were maintained in the specific-patho-
gen-free facility of the Hershey Medical Center and treated in accordance
with the National Institutes of Health and AAALAC International regu-
lations. Food and water were provided ad libitum, with MyD88/mice
receiving Baytril in chow and acidified water (pH 2.75) as antibacterial
measures. All animal experiments and procedures were approved by the
Penn State Hershey IACUC.
Viruses and infections. VACV (strain WR) stocks were produced in
143B.TK cell monolayers and ultracentrifuged through a 45% sucrose
cushion to purify viral particles from other cellular debris. For intrader-
mal infection, mice were sedated using ketamine-xylazine and injected in
each ear pinnawith 104 PFUofVACV in a volumeof 10l. For i.v. and i.p.
infection, mice were injected with 106 or 107 PFU of VACV in a volume of
500 l. For assaying neutralizing antibodies in serum, VACV-NP-
SIINFEKL-GFP (34) was used to infect B6/WT-3 cells. Wild-type VACV
(Western Reserve strain) was used in all other experiments.
To assess dermal pathogenesis, ear thickness was measured using a
0.0001-in. dial micrometer (Mitutoyo), and lesion progression was mea-
sured using a ruler. To analyze the presence of replicating virus, organs
were harvested, subjected to three freeze-thaw cycles in Hanks balanced
salt solution (HBSS), ground in a 7-ml Dounce homogenizer, and soni-
cated. Lysate was placed on a monolayer of 143B.TK cells, and plaques
were counted 2 days later. 143B.TK and B6/WT-3 cells were maintained
in Dulbecco modified Eagle medium (DMEM) with 5% fetal bovine se-
rum (FBS) (HyClone).
Flow cytometry of cells at the site of infection. Ear pinnae were cut
into strips and digested in 1 mg/ml collagenase XI (Sigma) for 60 min at
37°C. Live cells were blocked and stained on ice in 2.4G2 cell supernatant
containing 10% normal mouse serum (Sigma). Antibodies included
CD11b (M1/70), CD11c (N418), CD8 (53-6.7), B220 (RA3-6B2), and
Ly6G (1A8) from eBioscience and Ly6C (clone AL-21), CD45.2 (104),
CD19 (1D3), CD90.2 (53-2.1), NK1.1 (PK136), IL12p40/p70 (C15.6),
and IL-6 (MP5-20F3) from BD Pharmingen. Phycoerythrin (PE)-Cy7-
streptavidin (BD) was used to label biotin-conjugated antibodies. Den-
dritic cell (DC) subsets were identified as follows: B220 “plasmacytoid”
DCs (CD19 CD90NK1.1 CD11c CD11b B220), CD11b “con-
ventional” DCs (CD19 CD90 NK1.1 CD11c CD11b B220
CD8), and CD8 “lymphoid resident” DCs (CD19 CD90 NK1.1
CD11cCD11bB220CD8). Sample acquisitionwas performedwith
an LSRII flow cytometer (BD), and data were analyzed with FlowJo soft-
ware (TreeStar).
Analysis of neutralizing antibodies in serum. Mice were deeply se-
dated with ketamine-xylazine, and a 25-gauge 5/8-in. needle was inserted
below the xiphoid process to draw 400 to 800 l blood from the heart.
Serum was obtained by repeated centrifugation to remove all cells, fol-
lowed by at least one freeze-thaw cycle. Serum was serially diluted in
normal mouse serum and incubated at 37°C with VACV-NP-SIINFEKL-
GFP. After 1 h, virus-serummixtures were added to WT-3 cells at a mul-
tiplicity of infection (MOI) of 10:1 and incubated on a rotating rack at
37°C. Infectivity was measured as the percentage of green fluorescent
protein-positive (GFP) cells after 6 h of incubation with virus. Sample
acquisition was performed with a FACSCanto flow cytometer (BD), and
data were analyzed with FlowJo.
Intracellular cytokine staining. Spleens were digested using 1 mg/ml
collagenase D (Roche) for 30 min at 37°C and a 10-min ammonium-
chloride-potassium (ACK) lysis to lyse red blood cells. The resulting
splenocytes were stimulated with infectious VACV at an MOI of 10 in
DMEMwith 5%FBS for a total of 6 h. During the last 4 h of incubation, 10
g/ml brefeldin A (Sigma) was added to the medium. To detect intracel-
Davies et al.
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lular cytokines, cells were fixed in 1% formaldehyde (AcrosOrganics) and
stained and washed in 2.4G2 cell supernatant containing 10% normal
mouse serum and 0.5% saponin (Sigma). Sample acquisition was per-
formed with an LSRII flow cytometer, and data were analyzed using
FlowJo.
ELISpots. Previously defined VACV major histocompatibility com-
plex (MHC) class I and II epitopes (35) were screened for reactivity
against splenocytes fromWT C57BL6, TLR2/, andMyD88/mice at
10 days post-VACV ear infection. Splenocytes from naive mice were used
as antigen-presenting cells (APCs). Naive splenocytes were incubated
with the indicated peptide (final concentration, 2 g/ml) in 37°C, 5%
CO2. VACV-primed and peptide-pulsed splenocytes were then coincu-
bated overnight, and IFN--positive T cell responses were assayed by
IFN- enzyme-linked immunosorbent spot assay (ELISpot) (BD). Spots
were counted using ImmunoSpot software (CTL). Peptides were synthe-
sized by New England Peptide (Gardner, MA).
Real-time PCR. The extraction of total RNA from tissue and reverse
transcription of RNA were carried out as described previously (36), and
the PCR was done as before (37). The following dye combinations were
used for detection and data normalization: 6-carboxyfluorescein (FAM)
(reporter for IFNs, MX-1, and IL-6) and hexachlorofluorescein (HEX)
(reporter for glyceraldehyde-3-phosphate dehydrogenase [GAPDH]).
RESULTS
TLR2 is superfluous in controlling intradermal VACV infec-
tion. To examine the role of TLR2 in poxvirus recognition, we
infected mice via the natural intradermal (i.d.) route in the ear
pinnae with 104 PFU of VACV andmonitored pathology and viral
replication. TLR2/mice were indistinguishable fromwild-type
mice in the degree and rate of ear swelling (Fig. 1A). Following the
initial period of skin infection in which uncontrolled viral repli-
cation spurs recruitment of inflammatorymonocytes, a lesion de-
velops and is observed on both the inoculated convex surface and
the smoother concave surface of the ear. Viral replication de-
creases past day 5 of infection and is no longer detectable once the
lesion is resolved by loss of necrotic tissue (22). Tissue damage
develops more aggressively in many immunodeficient mouse
strains (38–40), but in TLR2/ mice, we observed that the pa-
thology developed similarly to that in wild-type (WT) mice (Fig.
1B). At no stage of intradermal infection was there significantly
more VACV replication in TLR2/mice than in WT mice (Fig.
1C), although 7 of 12 TLR2/ mice, compared to 4 of 12 WT
mice, had some detectable virus remaining on day 16. VACV nor-
mally remains restricted to the ear pinnae following i.d. infection,
but components of the immune system are required to prevent
systemic spread (38), and these components may be distinct from
those that control virus replication locally. Therefore, we also
looked for evidence that TLR2 restricted the spread of virus from
the ear pinnae both by quantification of virus titers in the primary
site of replication following systemic infection, the ovaries, and by
evaluation of morbidity following VACV infection. In multiple
experiments, TLR2/ mice had no detectable VACV in ovaries
above that detected inWTmice (Fig. 1D), did not loseweight (Fig.
1E), and had no visible signs of systemic infection such as tail
lesions. These data indicate that a successful innate response to a
natural route of VACV infection did not depend on TLR2.
TLR2 contributes to activation of dendritic cells by VACV in
vitro but not recruitment of myeloid cells in vivo. The results
above led us to inquire as to whether our stock of VACV was
capable of activating dendritic cells through TLR2 in vitro. We
harvested splenocytes from naive TLR2/ orWTmice and stim-
ulated them with VACV before adding brefeldin A to block cyto-
kine secretion. Cells were stained with antibodies for CD11c and
other markers of dendritic cell subsets to divide DCs (CD19
CD90 NK1.1 CD11c) into “plasmacytoid” DCs (CD11b
B220), “conventional” DCs (CD11b B220 CD8), and
CD8 “lymphoid resident” DCs (CD11b B220 CD8). The
cells were also stained to reveal production of the proinflamma-
tory cytokines IL-6 and IL-12. Though VACV is not as potent a
stimulus as ECTV (not shown), more IL-6 and IL-12 were de-
tected in VACV-stimulated cells than in unstimulated cells.
TLR2/ DCs expressed lower levels of IL-6 (Fig. 2A) and IL-12
(Fig. 2B) than did WT DCs. Although it has been suggested that
many reported TLR2 ligands are artifacts of contamination (13),
we observed that the cytokine production triggered by sucrose
cushion-purified VACV was at least as TLR2 dependent as that
produced following exposure of splenocytes to crude lysate from
VACV-infected cells (not shown).
Our in vitro results concur with other investigators’ findings
that TLR2 is important early in infection for production of proin-
flammatory cytokines, particularly IL-6 (25, 33). We investigated
FIG 1 TLR2 does not contribute significantly to the innate response to intra-
dermal VACV infection. C57BL/6 (black) or TLR2/ (white) mice were in-
fected intradermally with 104 PFU VACV in each ear pinna. (A) Ear swelling
wasmonitored with a thickness gauge until tissue loss began (n 10 ears). (B)
The size of lesions (solid lines) and subsequent loss of tissue (dotted lines) were
monitored for 3 weeks (n  10 ears). Results are representative of two inde-
pendent experiments. (C andD)On the specified day postinfection,mice were
sacrificed; ears (C) and ovaries (D) were freeze-thawed 3 times, homogenized,
and sonicated to release virions; and serial dilutions were applied to cellmono-
layers for VACV titer determination. (E) Weight loss was monitored for 3
weeks (n 5). Dotted lines indicate the limit of detection for virus plaque titer
assays. dpi, day postinfection.
TLR2-Independent MyD88 Activation by Intradermal VACV
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whether this deficit had practical importance in the recruitment of
cells to the site of acute infection. The normal course of cell re-
cruitment in the intradermal VACV model involves minimal
swelling until day 3; an influx of classical inflammatorymonocytes
which peaks at day 5; then development of lesions and entry of
tissue-protective CD11b Ly6G cells, which are attracted by un-
knownmechanisms and outnumber inflammatory monocytes by
day 7; and a large number of lymphocytes (especially CD8 T
cells), along with continued influx of Ly6G cells, on days 9 to 11
(38). We used flow cytometry to characterize cells in the infected
ears as infiltrating myeloid cells (CD45 FSCHI CD11b CD19
CD90NK1.1) and then as dendritic cells (CD11c), inflamma-
tory monocytes (CD11c Ly6CHI Ly6G), or tissue-protective
Ly6G cells (CD11c Ly6CMED Ly6G) (Fig. 3A). For each of
these subsets,WTandTLR2/mice showed similar adherence to
the predicted kinetics of cell recruitment (Fig. 3B toD). These data
indicate that any role for TLR2 in stimulating the secretion of
chemoattractants is not essential for attracting the cells most im-
portant for controlling VACV infection.
One of the most obvious reported deficiencies in TLR2/
mice challenged i.v. with VACV is their impaired secretion of IL-6
(33) or production of type I interferons (17). Therefore, to expand
our investigations, we measured induction of transcripts of type I
interferons, the interferon-inducible geneMX-1, or IL-6, on day 1
or day 7 after infection with VACV in the ear of TLR2/ mice
versus wild-type mice by quantitative PCR.We found that induc-
tion of IL-6 and MX-1 transcripts was not reduced in TLR2/
mice versus those in WT mice on either day 1 or day 7 postinfec-
tion. Similarly, induction of type I interferons inWT or TLR2/
mice was not reduced (and may have been slightly enhanced) on
day 1 postinfection and was in a similar range on day 7 postinfec-
tion. To expand our results, we examined the induction of tran-
scripts inmice lackingMyD88 or in LysM:wt/creMyD88:flox/flox
mice, which have the MyD88 gene deleted specifically in myeloid
cells, including those that infiltrate the site of infection. Surpris-
ingly, we found little difference in any of the transcripts examined
in either knockout strain (Fig. 4), indicating a MyD88-indepen-
dent redundant pathway in the induction of these genes following
i.d. VACV infection. Furthermore, IL-6 was not important for
control ofVACV following i.d. infection as virus titers and recruit-
ment ofmyeloid cells were similar in IL-6 knockout andwild-type
mice (not shown).
TLR2 may play a limited role in control of virus dissemina-
tion following systemicVACV infection.To attempt to reconcile
our above findings with the published work that describes a role
for TLR2 in control of VACV infection, we systemically infected
TLR2/ mice and WT mice with much larger inocula (up to 3
FIG 2 TLR2 contributes to in vitro activation of dendritic cells by VACV.
Splenocytes pooled from three naive C57BL/6 (black) or TLR2/ (white)
mice were treated with brefeldin A to block secretion, stimulated for 6 h with
VACV at an MOI of 10, and stained to measure intracellular IL-6 (A) or
intracellular IL-12 (B) production by dendritic cell (CD19 NK1.1 CD90
CD11c) subsets. The three subsets are “conventional” CD11b DCs
(CD11c CD11b B220 CD8), “plasmacytoid” B220 DCs (CD11c
CD11b B220), and “lymphoid-resident” CD8 DCs (CD11c CD11b
B220 CD8). Values shown are geometric mean fluorescent intensity
(MFI), normalized to geometric MFI of unstimulated cells. Cells stimulated
with lysate from uninfected cells gave results similar to those for unstimulated
cells. These results are representative of three independent experiments.
FIG 3 Lack of TLR2 does not significantly affect recruitment of innate immune cells to the site of intradermal vaccinia virus infection. C57BL/6 (black) or
TLR2/ (white) mice were infected intradermally with VACV in each ear pinna. On days 2, 5, 7, and 9 postinfection, mice were sacrificed and cells from ear
pinnaewere stained for flow cytometry.Myeloid cell subsets were identified byCD45positivity,morphology, and the gating strategy depicted in panel A. For each
mouse, the number of CD11c cells (B), CD11b Ly6CG cells (C), and CD11b Ly6CG cells (D) was calculated as a percentage of all CD45 FSCHI cells.
These results are representative of two independent experiments with 2 to 3 samples in each group.
Davies et al.
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logs higher) than those used intradermally and monitored mice
for 32 days for morbidity or mortality. During systemic VACV
infection (i.p. or i.v.), the initial stage of immune mobilization is
spurred by viremia and viral replication in internal organs and
may be followed by skin lesions visible on the tails of mice (34, 41,
42)—akin to the progression of ECTV infection or smallpox but
markedly less virulent (43, 44). In our system, i.v. infection with
107 PFU is followed by weight loss that reaches a peak on day 5
postinfection. By day 5, the tails of infected mice become swollen
and appear limp, and individual pocks are not evident until day 6,
when they become distinguishable as discolored or ulcerated hair-
less spots. By day 9, the swelling recedes, and pocks begin to heal
and appear as pale patches.
Using 12 mice in each group, we saw that VACV-infected
TLR2/ and WT mice displayed similar kinetics of weight loss
and recovery (Fig. 5A). All mice survived infection, but TLR2
knockouts had a statistically greater number of pocks on the tails
(Fig. 5B) and were more prone to losing skin altogether near the
tail tip (Fig. 5C). MyD88/ mice were also more susceptible to
i.v. infection, suffering severe weight loss and mortality (Fig. 5D),
which was notably increased in comparison to both WT and
TLR2/mice.
VACV is normally cleared from the liver and other internal
organs after about a week (45, 46) but is particularly tropic for
FIG 4 MyD88-independent induction of inflammatory genes at the site of
infection. Female mice of WT, TLR2/, MyD88/, and LysMwt/cre
MyD88flox/flox strains were infected in each ear pinna with 104 PFU of band-
purifiedVACV strainWR. At 24 h or 7 days postinfection, the right ear was cut
into strips and frozen at 80°C in RNAlater. Total RNA was extracted and
reverse transcribed into cDNAwhich was used as the template for quantitative
real-time PCR, with primers specific for IL-6 (Il6), MX-1 (Mx1), IFN- (all
IFN- transcripts except Ifna4), IFN-1 (Ifnb1), or the housekeeping gene
Gapdh. Sample sizesweren 4 for naive ears,n 2 for day 1, andn 3 for day
7. Results shown are typical of two independent experiments.
FIG 5 TLR2 contributes to defense against disseminated vaccinia virus infection. (A to C) C57BL/6 (black) or TLR2/ (white) mice were infected with 107 PFU of
VACVi.v. andmonitored forweight loss (A) andpathogenesis (n12). Pockswereobservedonlyon the tail andwere counteddaily (B), alongwith theobservation that
somemice had significant loss of necrotic tissue at the tail tip (C). (D)C57BL/6 (black) orMyD88/ (gray)micewere infectedwith 107 PFUVACV i.v. andmonitored
for weight loss and pathogenesis (n 4). Daggers indicate MyD88/ mouse mortality. The one MyD88/ mouse alive at 10 days p.i. continued to survive until
sacrificed (21 days p.i.). (E) On the specified days after infection with 107 PFU of VACV i.v., mice were sacrificed, ovaries were homogenized, and serial dilutions were
applied to cell monolayers to determine VACV titer. (F)Mice were infected with the specified inoculum of VACV through the specified route. At 3 days postinfection,
mice were sacrificed, ovaries and livers were homogenized, and the VACV titer was measured as stated above. ***, P	 0.001; **, P	 0.01; *, P	 0.05.
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ovarian follicles and can be detected there after it has been cleared
from all other organs (47). We saw that TLR2/ and WT mice
infected with VACV i.v. had similar titers during the peak of viral
replication, and there was no evidence that TLR2/ mice were
slower to clear the infection (Fig. 5E). In addition to i.v. infected
mice, we looked at VACV replication at an early/peak time point
(72 h) in mice infected with 107 PFU or 106 PFU i.p. In none of
these infection models did TLR2/ mice have more viral repli-
cation in either the liver or the ovaries (Fig. 5F).Other studies have
examined VACV levels in the liver following infection (17, 33).
The liver is one of themajor sites of replication for ECTV (48), but
following infection with VACV, titers in the liver typically do not
approach those observed in the ovaries. As expected, we found
that titers in the liver were 3 to 5 logs lower than those found in the
ovaries, and there was no discernible difference between titers
found in WT and TLR2/mice. Our data suggest that TLR2/
mice are capable of controlling VACV infection in the internal
organs, but the observation of increased lesions on TLR2/ in-
fected mice supports a model in which TLR2 signaling, probably
in phagocytes, limits the dissemination of the virus.
TLR2-independent MyD88 signaling is important for adap-
tive anti-VACV immunity. Although it appears that TLR2 is su-
perfluous for viral control and an innate immune response, we
examined whether it may play a role in establishing the adaptive
immunity that makes VACV such a valuable tool for immuniza-
tion. CD8 T cell responses have been described to be dependent
upon cell-intrinsic MyD88 following intranasal infection (28), a
model in which the T cell response is required for protection.
Following i.d. infection, T cells alone are not required for protection
or to restrictVACVspread fromtheear (38, 49), butweexamined the
role of TLR2 andMyD88 in regulation of CD4 responses (which do
have a role following i.v. infection [42]) following i.d. infection. We
used a library of peptides containing class II-restricted epitopes that
are targetedbya significantnumberofTcells afterVACVinfectionof
mice (35). The number of functional splenic T cells targeting each
peptide, 10 days postinfection, was assayed using gamma interferon
ELISpot. Similar numbers of T cells targeting each of 17 class II-
restricted epitopes detected at levels above background (Fig. 6) were
found in in TLR2/ mice and WT mice. However, in MyD88/
mice, all 17 epitopes stimulated fewer T cells than inWTmice, with a
significant difference for 7 of the 17.
CD4 T cell-dependent production of antibody is required for
effective protection following i.v. challenge with VACV (42), so
we examined whether the lack of MyD88 (or TLR2) that had an
effect upon CD4 responses impacted the production of neutraliz-
ing antibody. We isolated serum either during acute i.d. infection
(10 days postinfection) or after mice had successfully resolved the
infection (32 days postinfection). To assay for the presence of
neutralizing antibodies, we made serial dilutions of cell-free se-
rum and then mixed serum with a strain of VACV engineered to
express GFP upon infection of a target cell. Virus-serummixtures
were incubated with the murine WT-3 cell line, and the percent-
age of GFP cells was determined by flow cytometry. At both
postinoculation time points (Fig. 7A and B), sera from WT and
TLR2/mice were equally capable of neutralizing VACV infec-
tivity. However, MyD88/ sera had significantly lower levels of
neutralizing antibody both during acute infection (Fig. 7C) and
during the early stages of humoral memory (Fig. 7D). Therefore,
our conclusions on the significance of MyD88 signaling for adap-
tive immunity are limited to B cells and CD4 T cells. These data
indicate that TLR2 alone does not play a role in establishing adap-
tive immunity to VACV, but at least one receptor upstream of
MyD88 does play a major role.
TLR2-independent MyD88 signaling is needed for optimal
control of intradermal VACV infection. If redundancy in the
innate immune system means that TLR2 alone is not required,
there may still be a requirement for TLR2 in combination with
otherMyD88-dependent pathways. Synergy between two ormore
TLRs has been found to be important in other viral infections (10,
50). Therefore, we looked for evidence that other MyD88-depen-
dent receptors are involved in controlling VACV replication and
pathogenesis in this natural route of infection.
When observing the pathogenesis of intradermal VACV, we
saw that the kinetics of ear swelling were the same in MyD88/
andWTmice (Fig. 8A), suggesting that there was no deficit in the
immediate inflammatory mediators responsible for vascular per-
meability. Ear lesions spread at similar rates in the two mouse
strains, but tissue loss proceeded at a slightly higher rate in
MyD88-deficient mice, suggesting more tissue necrosis (Fig. 8B).
When virus titers in the ear pinnae were measured on day 3, 5, or
7 postinfection, MyD88/mice showed significantly more viral
replication (Fig. 8C), a particularly profound finding as virus rep-
lication occurs similarly despite large differences in the inoculat-
ing dose (22). This difference was not detected on day 10, due
partially toMyD88/mice losingmore of the tissue in which the
virus replicates. The enhanced viral replication in MyD88 knock-
outs was not observed in LysM:wt/cre MyD88:flox/flox mice,
which have the MyD88 gene deleted specifically in myeloid cells
(Fig. 8D). Finally, we looked for viral replication in the ovaries on
day 5 postinfection and saw no VACV in either MyD88/ or
wild-type mice (data not shown), further suggesting that there is
no impairment in the function of the myeloid phagocytes that
block viral spread from the site of infection. However, these data
show a clear role for TLR2-independent MyD88 signaling in the
timely control of VACV replication at the site of active infection,
as well as in the mobilization of lymphocytes to protect against
future poxvirus challenges.
FIG 6 TLR2-independent MyD88 signaling is required for an optimal anti-
VACVCD4T cell response. C57BL/6 (black), TLR2/ (white), orMyD88/
(gray) mice were infected intradermally with VACV in each ear pinna. On day
10 postinfection, mice were sacrificed and splenocytes were stimulated by na-
ive splenocytes that had been pulsed with a library of MHC class II-restricted
poxviral peptides. Each bar represents pooled T cells from three spleens, with
error bars showing the standard error of the mean for two experimental rep-
licates. *, P	 0.05 in unpaired t test of C57BL/6 and MyD88/ samples.
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DISCUSSION
A lack of TLR2 has been shown to confer increased susceptibility
to a wide range of infections (51). However, the majority of these
publications examine bacterial infections. Among the few viruses
with established TLR2 ligands are measles virus (52), hepatitis C
virus (HCV) (53), Epstein-Barr virus (54), andmultiple herpesvi-
ruses bearing glycoproteins gB and gL/gH (55). There is some
evidence that TLR2 polymorphisms influence the success of mea-
FIG 7 TLR2-independent MyD88 signaling is required for optimal humoral immunity following VACV infection. (A and B) C57BL/6 (black) or TLR2/
(white) mice were infected intradermally with VACV in each ear pinna. Mice were sacrificed on day 10 (A) or day 32 (B) postinfection. Serial dilutions of serum
were incubated with VACV-NP-S-EGFP to test their ability to neutralize viral infectivity. Serum-virus mixtures were applied toWT-3 cells for 6 h at anMOI of
10:1, and the percentage of cells that became enhanced GFP positive (EGFP) was quantified using flow cytometry. (C and D) C57BL/6 (black) or MyD88/
(gray)micewere infected intradermally withVACV in each ear pinna.Micewere sacrificed on day 10 (C) or day 32 (D) postinfection, and neutralizing antibodies
in serum were measured as stated above. ***, P	 0.001; **, P	 0.01; *, P	 0.05.
FIG 8 TLR2-independentMyD88 signaling contributes to clearance of VACVduring intradermal infection. C57BL/6 (black) orMyD88/ (gray)mice were infected
intradermallywithVACVineachearpinna. (A)Ear swellingwasmonitoredwitha thicknessgaugeuntil tissue lossbegan(n10ears). (B)The sizeof lesions (solid lines)
and subsequent loss of tissue (dotted lines) were monitored for 3 weeks (n  10 ears). (C) On the specified day postinfection, mice were sacrificed, ears were
homogenized, and serial dilutions were applied to cellmonolayers for VACV titer determination. (D)C57BL/6 (black) or LysMwt/creMyD88flox/flox (shaded)micewere
infected with VACV as stated above, and at day 7, mice were sacrificed and ears were homogenized for titer determination. ***, P	 0.001; **, P	 0.01; *, P	 0.05.
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sles vaccination (56), and HCV patients with a deletion in the 5=
untranslated region (UTR) of TLR2 have more risk of hepatocel-
lular carcinoma (57). Epstein-Barr virus (EBV), HCV, and mea-
sles virus do not infect mice, but following herpes simplex virus 1
(HSV-1) infection, TLR2/mice appear to have a deficit in pro-
inflammatory cytokine secretion, making them more susceptible
to periocular herpetic lesions but more resistant to corneal kera-
titis after eye infection (58), as well as more resistant to encepha-
litis after intracranial infection (59). With another herpesvirus,
mouse cytomegalovirus (MCMV), one study observed enhanced
susceptibility in TLR2 knockouts (60), in contrast to other find-
ings that MyD88 knockouts are susceptible but TLR2 knockouts
are not (61, 62). These are among the few in vivo studies showing
viral susceptibility in TLR2 knockout mice.
Although VACV is known to be recognized by TLR2 in vitro,
the evidence gleaned from in vivo experiments is inconsistent. In
addition to repeated observations that proinflammatory cytokine
production is blunted in TLR2 knockouts, Yang and colleagues
have seen enhanced viral replication in ovaries of TLR2/mice at
day 2 or 3 post-i.p. infection (25, 63), while Nolan and colleagues
saw that viral replication was similar at early time points post-i.v.
infection but persisted for longer in TLR2/ mice (33). In this
study, we indirectly confirm that TLR2/ mice are marginally
more susceptible to VACV dissemination, by observing enhanced
skin pathogenesis on the tail, but we did not find any difference in
viral titers at either early or late time points. Differences between
our results and those of others may be the result of many varia-
tions in the experimental protocol, including the type of cell cul-
ture cells used to grow virus, the method of purifying virus, and
the strain of mice used to measure virus pathogenesis and titers.
Also, the Nolan laboratory found delayed VACV clearance by
measuring viral gene expression with a luciferase reporter assay,
while wemeasured infectious viral particles with a plaque assay. In
addition, Barbalat et al. proposed that TLR2-mediated recogni-
tion of VACV by myeloid cells induced significant production of
type I IFN and that this controlled virus replication in vivo (17).
However, we found little induction of type I IFN following i.d.
infection with VACV, a result that echoes a previous observation
following i.v. infection (64), and any induction observed was in-
dependent of both TLR2 and MyD88.
We have also conducted a novel investigation of the signifi-
cance of TLR2 and MyD88 via the more physiologically relevant
intradermal route of infection with VACV. In this system, unlike
artificially induced systemic infection, TLR2 proved to be com-
pletely redundant for restricting the pathogenesis caused by
VACV. Typically, we used a much higher dose (106 PFU) when
infecting i.v. than when infecting i.d. (104 PFU). However, even
when we infected i.d. with 106 PFU, a dose that is known to allow
systemic spread of VACV (22), we did not observe a difference in
pathogenesis between WT and TLR2/ mice (not shown).
Therefore, it is likely that the route of infection, rather than the
size of the viral inoculum, accounts for the observed differences.
When investigated further for deficiencies of the innate or adap-
tive immune system, TLR2 knockouts were also indistinguishable
fromWTmice in recruitment of myeloid cells to the site of infec-
tion, proliferation of VACV-specific T cells, and production of
VACV-neutralizing serum antibodies. Finally, with respect to
control of the virus, at no point from day 1 to day 22 postinfection
was there a significant difference betweenWT and TLR2/mice
in their viral titers in the ear, and there was no sign that TLR2
signaling was needed to block systemic spread of the virus. There-
fore, we believe that many of the in vitro observations of a role for
TLR2 in recognition of VACV may stem from contamination in
virus preparations. However, this does not rule out a minor re-
dundant role for TLR2 in recognition of viral components or dan-
ger signals induced by virus-infected cells during an in vivo infec-
tion, a process that can also be accomplished by other TLR or
inflammasome components.
MyD88/ mice also do not permit systemic spread of the
virus in our infectious model. However, they have a marked im-
pairment in the production of CD4 T cells and antibodies, and
they are less able to control viral replication in infected tissue. The
1.5-log increase in virus found in the ear on day 7 in mice lacking
MyD88 is important, as even inoculation with doses that differ by
3 to 4 logs produces similar levels of virus in the ear at this time
point (22). Our discovery that TLR2-independent MyD88 signal-
ing is important for anti-VACV immunity is compatible with an
earlier study using a variety of CD8 T cell assays, which found that
T cell expansion is impaired in MyD88/ mice post-i.p. infec-
tion, but we did not see this phenotype in TLR2 or IL-1R knock-
outs (28). Here, we found an effect on MHC class II-restricted
responses, indicating a MyD88-dependent process involved in
priming CD4 T cells following intradermal infection. Therefore,
our results do have a common theme in that both the CD4 and
CD8 T cell responses are MyD88 dependent and TLR2 and IL-1R
independent. This may indicate that the crucial MyD88 signaling
is downstream of one or more members of the IL-1R family (IL-
1R, IL-18R, and ST2). Exogenous IL-18 helps mice resolve VACV
infection (65, 66), although the importance of IL-18 and IL-1 in
this infection model is blunted by the virus’s repertoire of inflam-
masome inhibitors and soluble IL-18 and IL-1 binding proteins
(67). However, since the B16R protein is specific for IL-1 (68),
IL-1R may be more important in its role as receptor for the
alarmin IL-1. Indeed, overexpression of IL-1 helps to resolve
intradermal VACV infection (69). Recent findings also suggest a
role for ST2, which recognizes the alarmin IL-33 rather than an
inflammasome product (70). Alternately, there may be redun-
dancy in MyD88 signaling, with some cell types responding to
viral ligands or alarmins via TLR2, and some cell types responding
to inflammasome products or alarmins via IL-1R family mem-
bers. We have demonstrated that production of MyD88 by cells
expressing LysM, which include inflammatory monocytes and
“tissue-protective” myeloid cells recruited to the site of infection,
is not important for control of virus replication, prevention of
systemic spread of VACV, induction of the innate response, or a
tissue protective response. Indeed, MyD88 deficiency did not al-
low systemic spread of the virus following i.d. infection, indicating
that the recruitment and activation of the mononuclear phago-
cytes that we have previously shown to restrict VACV spread from
the skin (38) are MyD88 independent. The identity of the innate
sensor that recruits and activates these cells remains unknown.
Our data indicate that an increase in VACV virulence requires
multiple host MyD88-dependent pathways to be abrogated, an
observation that is common in the immune response to many
viruses. For the dsDNA herpesviruses HSV-1,MCMV, andmurid
herpesvirus 68 (MHV-68), more than one TLR contributes to
control of the infection (10, 50, 71). For example, during i.p.
MCMV infection, no effect of TLR7 single knockout is detectable,
but TLR7/9 double knockouts are more susceptible than TLR9
single knockouts (72). Similar results were seen with intranasal
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HSV-1, with TLR2 knockouts impaired in cytokine production
but not impaired in survival or viral clearance, while TLR2/9 dou-
ble knockouts had worse outcomes than did single knockouts
(10). In influenza virus infection, TLR7 alone seems to be required
for successful clearance of a primary infection (73), but inflam-
masome signaling through IL-1R is important for protective im-
munity (74).MyD88/mice are farmore susceptible to lympho-
cytic choriomeningitis virus (LCMV) infection, while TLR7/9
double knockouts and IL-1R knockouts show only partial suscep-
tibility (75, 76). The oncolytic effects of vesicular stomatitis virus
(VSV), abrogated similarly by both IFN-/R andMyD88 knock-
out, are not abrogated by removing either IL-1R or any of the
individual TLRs likely to recognize VSV (77). And, even in a case
where the protective effect of MyD88 is independent of IFN-/
(rabies virus), MyD88 signaling requires a combination of TLR7
and at least one other receptor (78).
Our results are compatible with an immune system in which,
for each pathogen, one or more pattern recognition receptors re-
spond with an immediate warning signal, which primes the im-
mune system for a robust response once more pronounced indi-
cators of infection develop, such as viral replication and necrosis.
TLR2 likely assists in early immune mobilization by upregulating
proinflammatory cytokines and IFN-/, as well as pro-IL-1
and pro-IL-18 that can then be cleaved and secreted by inflam-
masomes. However, during a physiological VACV challenge there
would be sufficient levels of these factors, even in the absence of
TLR2, to combat the infection equally well as long as inflam-
masome activation still occurs. In this scenario, TLR2 is necessary
only when the body is challenged by an artificially high inoculum
and may be more useful as part of a redundant suite of PRRs that
are continually activated by the various constituents of themicro-
biome to maintain a baseline level of innate immune readiness.
ECTV, another orthopoxvirus, is one example of a virus for which
the loss of a single TLR (TLR9) has a major effect on susceptibility
even with a small inoculum (26, 79), but there are few other vi-
ruses in that category and VACV does not appear to be one of
them.
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